A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.
This patient received the treatment in a clinical trial led by Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch at NCI’s Center for Cancer Research (CCR), and the findings were published June 4, 2018 in Nature Medicine. NCI is part of the National Institutes of Health.
“We’ve developed a high-throughput method to identify mutations present in a cancer that are recognized by the immune system,” Dr. Rosenberg said. “This research is experimental right now. But because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many types of cancer.”
The new immunotherapy approach is a modified form of adoptive cell transfer (ACT). ACT has been effective in treating melanoma, which has high levels of somatic, or acquired, mutations. However, it has been less effective with some common epithelial cancers, or cancers that start in the lining of organs, that have lower levels of mutations, such as stomach, esophageal, ovarian, and breast cancers.
In an ongoing phase 2 clinical trial, the investigators are developing a form of ACT that uses tumor-infiltrating lymphocytes (TILs) that specifically target tumor cell mutations to see if they can shrink tumors in patients with these common epithelial cancers. As with other forms of ACT, the selected TILs are grown to large numbers in the laboratory and are then infused back into the patient (who has in the meantime undergone treatment to deplete remaining lymphocytes) to create a stronger immune response against the tumor.
A patient with metastatic breast cancer came to the trial after receiving multiple treatments, including several chemotherapy and hormonal treatments, that had not stopped her cancer from progressing. To treat her, the researchers sequenced DNA and RNA from one of her tumors, as well as normal tissue to see which mutations were unique to her cancer, and identified 62 different mutations in her tumor cells.
The researchers then tested different TILs from the patient to find those that recognized one or more of these mutated proteins. TILs recognized four of the mutant proteins, and the TILs then were expanded and infused back into the patient. She was also given the checkpoint inhibitor pembrolizumab to prevent the possible inactivation of the infused T cells by factors in the tumor microenvironment. After the treatment, all of this patient’s cancer disappeared and has not returned more than 22 months later.
“This is an illustrative case report that highlights, once again, the power of immunotherapy,” said Tom Misteli, Ph.D., director of CCR at NCI. “If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers.”
Investigators have seen similar results using mutation-targeted TIL treatment for patients in the same trial with other epithelial cancers, including liver cancer and colorectal cancer. Dr. Rosenberg explained that results like this in patients with solid epithelial tumors are important because ACT has not been as successful with these kinds of cancers as with other types that have more mutations.
He said the “big picture” here is this kind of treatment is not cancer-type specific. “All cancers have mutations, and that’s what we’re attacking with this immunotherapy,” he said. “It is ironic that the very mutations that cause the cancer may prove to be the best targets to treat the cancer.”
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Immunotherapy Could Still Have Pivotal Role in Ovarian Cancer on September 18, 2018 at 1:07 pm
Although enthusiasm remains for developing immunotherapies for patients with ovarian cancer, phase II studies evaluating the treatment’s efficacy in the recurrent population have been disappointing th... […]
- Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non–Small-Cell Lung Cancer on September 18, 2018 at 9:28 am
ONCOLOGY spoke with Eric Ko, MD, PhD, a radiation oncologist at New York–Presbyterian Weill Cornell Medical Center in New York City, who recently published a review article with his colleagues on s... […]
- The Cancer Center at BIDMC Opens a Personalized Immunotherapy Cancer Vaccine Facility on September 17, 2018 at 1:51 pm
Newswise — BOSTON – The Cancer Center at Beth Israel Deaconess Medical Center (BIDMC) today announced the opening of the Randi and Brian Schwartz Family Cancer Immunotherapy and Cell Manipulation Faci... […]
- "As quick as you can get:" Toddler cancer free after 10 days of immunotherapy on September 16, 2018 at 6:24 am
SEATTLE, Wash. (KOMO) --Harper Beare is just shy of her second birthday, and almost everything about her is typical two-year-old. But this little girl has spent nearly half her life in and out of hosp... […]
- The cancer patient had exhausted his options. Enter immunotherapy. on September 14, 2018 at 1:03 pm
A year after doctors removed a tumor from Kevin Hill's body, his nightmare seemed to fade. At 26, he was happy, healthy and alive. He would touch the foot-long scar that stretches from his chest to si... […]
- Engineered natural killer cells may be the next great cancer immunotherapy on September 13, 2018 at 11:06 am
The cancer fighters known as CAR T cells have proved their prowess in recent years. Three therapies using the altered T cells against lymphoma or leukemia have won U.S. Food and Drug Administration ap... […]
- Doctors work to treat cancer with immunotherapy on September 13, 2018 at 9:36 am
(KAIT/NBC) - Doctors said one cancer patient’s result gave them new hope with a new cancer treatments, called ‘Immunotherapy’. In 2017, Ruth Wright learned her breast cancer had spread to her lungs, l... […]
- Cancer Immunotherapy Market Expected to Surpass 101.6 Billion by 2023 with Major Players as Celgene Corporation, Merck & Co and Amgen Inc on September 12, 2018 at 5:01 am
The Global Cancer Immunotherapy Market has been growing impressively and is expected to maintain the same momentum during the forecast period. Market Research Future (MRFR) projects that the global ca... […]
- Three Scientists to Receive Top Honors From the Cancer Research Institute for Outstanding Contributions to Cancer Immunology and Immunotherapy on September 10, 2018 at 2:50 pm
Newswise — NEW YORK, September 10, 2018—The Cancer Research Institute (CRI), a nonprofit organization dedicated to the discovery and development of immunotherapies for all forms of cancer, will bestow ... […]
via Bing News